Latest Articles about IRWD

Loss Widens at Ironwood - Analyst Blog

Zacks Equity Research — Thu, 25 Apr 2013 00:10:42 Z

Ironwood Pharmaceuticals, Inc. 's ( IRWD ) first-quarter 2013 loss of 87 cents per share compared unfavorably with the year-ago loss of 34 cents per share. Results were primarily hurt by

Loss Widens at IRWD on Higher Costs - Analyst Blog

Zacks Equity Research — Wed, 16 Jan 2013 20:40:01 Z

Ironwood Pharmaceuticals, Inc.'s ( IRWD ) fourth-quarter 2012 loss of 41 cents per share compared unfavorably with the year-ago loss of 7 cents per share. Results were hurt by higher

Alkermes Maintains Fiscal 2013 View - Analyst Blog

Zacks Equity Research — Thu, 10 Jan 2013 04:40:01 Z

Alkermes plc ( ALKS ) recently reaffirmed its view for fiscal 2013 (ending March 31, 2013). The company continues to expect adjusted earnings per share in the range of $0.88-$1.02. The

Forest Settles with Glenmark - Analyst Blog

Zacks Equity Research — Thu, 10 Jan 2013 03:00:01 Z

Forest Laboratories, Inc. ( FRX ) recently entered into a settlement agreement with Glenmark Pharmaceuticals Ltd., relating to its patent infringement litigation for Bystolic (nebivolol).

Catalyst-Filled 2013 for Onyx - Analyst Blog

Zacks Equity Research — Thu, 10 Jan 2013 00:00:30 Z

Onyx Pharmaceuticals, Inc. ( ONXX ) recently provided an update on its performance in 2012 and its plans for 2013. Kyprolis Off to a Strong Start Oncology product Kyprolis, which was

Upbeat 2013 from ViroPharma - Analyst Blog

Zacks Equity Research — Wed, 09 Jan 2013 03:29:01 Z

ViroPharma Incorporated ( VPHM ) recently provided guidance for 2013. ViroPharma expects net product sales between $450 million and $475 million in 2013 on a worldwide basis.

Cubist Reports Impressive 4Q Sales - Analyst Blog

Zacks Equity Research — Wed, 09 Jan 2013 01:43:01 Z

Cubist Pharmaceuticals Inc. 's ( CBST ) unaudited net revenues for the fourth quarter of 2012 climbed 16% year over year to $245.9 million, driven by strong sales of its antibiotic

Ironwood Winds Up Debt Offering - Analyst Blog

Zacks Equity Research — Tue, 08 Jan 2013 03:50:01 Z

Entrepreneurial pharmaceutical company, Ironwood Pharmaceuticals, Inc. ( IRWD ) recently announced that it has completed the offering of $175 million Linaclotide PhaRMA 11% notes. The note

Impax Launches Opana ER Generic - Analyst Blog

Zacks Equity Research — Tue, 08 Jan 2013 00:52:01 Z

Global Pharmaceuticals, the generic division of Impax Laboratories, Inc. ( IPXL ), a specialty pharmaceutical company, recently started shipping its generic version of Endo Health

FDA Approval for Salix Drug - Analyst Blog

Zacks Equity Research — Mon, 07 Jan 2013 22:50:01 Z

Salix Pharmaceuticals, Ltd. ( SLXP ) recently said that the FDA has approved the company's anti-diarrhea drug for HIV/AIDS patients. Fulyzaq (crofelemer) 125 mg delayed-release tablets

Watson's Generic Product Approved - Analyst Blog

Zacks Equity Research — Mon, 07 Jan 2013 21:00:01 Z

Watson Pharmaceuticals, Inc. ( WPI ) recently announced that it gained US Food and Drug Administration (FDA) approval for its generic version of Ferring Pharmaceuticals' Lysteda (tranexamic

Valeant Upbeat About 2013 - Analyst Blog

Zacks Equity Research — Mon, 07 Jan 2013 19:17:01 Z

Valeant Pharmaceuticals International Inc. ( VRX ) recently provided its guidance for 2013. Valeant expects to generate additional revenue of about $1 billion in 2012, despite a $200

Patent Challenge for Auxilium Pharma - Analyst Blog

Zacks Equity Research — Sat, 05 Jan 2013 04:17:01 Z

Auxilium Pharmaceuticals, Inc. ( AUXL ) and Xstelos Holdings, Inc. ( XTLS ) recently received a notice from Upsher-Smith Laboratories, Inc. regarding the filing of a 505(b)(2) new

Positive Results on SGYP Candidate - Analyst Blog

Zacks Equity Research — Fri, 04 Jan 2013 02:30:01 Z

Synergy Pharmaceuticals ( SGYP ) recently presented positive results from a phase IIb/III study on its chronic idiopathic constipation (CIC) candidate, plecanatide. The study met its

Ironwood Pharma Upped to Strong Buy - Analyst Blog

Zacks Equity Research — Fri, 04 Jan 2013 00:14:01 Z

On January 2, 2013, Zacks Investment Research upgraded Ironwood Pharmaceuticals, Inc.'s ( IRWD ) to a Zacks #1 Rank (Strong Buy). Why the Upgrade? Ironwood Pharma has been buoyed by a